Season 2025 Episode 703
GT Biopharma (NASDAQ: GTBP) is pioneering a new era in cancer treatment: one that replaces cutting, burning, and poisoning with precision, safety, and the power of the body’s own immune system.
In this interview, Executive Chairman & CEO Michael Breen and Consulting Senior Medical Director Dr. Jeffrey Miller discuss how GT Biopharma’s TriKE® technology harnesses natural killer (NK) cells to target and destroy cancer cells, offering a more humane alternative to traditional therapies. They talk about the science behind their platform, the progress of ongoing Phase 1 clinical trials for blood cancer, upcoming FDA filings for solid tumors, and how next-generation nanobody and camelid technology is advancing efficacy and safety.
Discover why GT Biopharma’s platform represents one of the most promising innovations in immunotherapy and why investors are watching closely as key data milestones approach.
Learn more about GT Biopharma: https://www.gtbiopharma.com/
Watch the full YouTube interview here: https://youtu.be/he9i0aJQ2JM
And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia
Published on 2 months ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate